The iMMagine-1 trial has an estimated enrolment of 110 participants and a primary completion date of May 2024, according to ClinicalTrials.gov. Arcellx has said it plans to initiate enrollment in another Phase II study, dubbed iMMagine-2, to evaluate CART-ddBCMA in earlier-line populations with multiple myeloma.
The setback hampers Gilead and Arcellx's pursuit of rival BCMA-directed CAR-T therapies already on the market; namely Johnson & Johnson and Legend Biotech's Carvykti (ciltacabtagene autoleucel), as well as Bristol Myers Squibb and 2seventy bio's Abecma (idecabtagene vicleucel). Sales of Abecma reached $147 million in the first quarter, while Carvykti brought in $72 million.$Arcellx(ACLX)$